Standards, options and recommendations (SOR) for endocrine therapy in patients with non metastatic breast cancer;Standards, options et recommandations (SOR): Hormonotherapie dans les cancers du sein non metastatiques

Bulletin du Cancer

Volumn 87, Issue 6, 2000, Pages 469-490

  Mauriac, Louis ^a   Blanc Vincent, Marie Pierre ^b   Luporsi, Élisabeth ^c   Cutuli, Bruno ^d   Fourquet, Alain ^e   Garbay, Jean Rémi ^f   Giard, Sylvia ^g   Spyratos, Frédérique ^h   Zafrani, Brigitte ^e   Dilhuydy, Jean Marie ^a  

^a INSTITUT BERGONIÉ   (France)

^b FNCLCC   (France)

^c CENTRE ALEXIS VAUTRIN   (France)

^d Polyclinique de Courlancy   (France)

^e INSTITUT CURIE   (France)

^f INSTITUT GUSTAVE ROUSSY   (France)

^g CENTRE OSCAR LAMBRET   (France)

^h CENTRE RENÉ HUGUENIN   (France)

Author keywords

Adult; Cancer; Chemohormonal therapy; Endocrine therapy; Guidelines; Hormonal antineoplastic agents; Hormonal treatment; Neoplasms; Non metastatic breast neoplasms

Indexed keywords

ANTIESTROGEN; TAMOXIFEN;

ANTINEOPLASTIC ACTIVITY; BREAST CANCER; CANCER PATIENT; HEALTH CARE QUALITY; HORMONAL THERAPY; HUMAN; POSTMENOPAUSE; PRACTICE GUIDELINE; PREMENOPAUSE; REVIEW; RISK BENEFIT ANALYSIS;

ANTINEOPLASTIC AGENTS, HORMONAL; AROMATASE INHIBITORS; BREAST NEOPLASMS; ENZYME INHIBITORS; ESTROGEN ANTAGONISTS; FEMALE; GONADOTROPIN-RELEASING HORMONE; HUMANS; OVARY; POSTMENOPAUSE; PREMENOPAUSE; PROGESTINS; TAMOXIFEN;

EID: 0033940160     PISSN: 00074551     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (147)

1. 1. Andersson M, Srorm HH, Mouridsen HT. Incidence of new primary cancers, after adjuvant tamoxifen therapy and radiotherapy for early breast cancer. J Natl Cancer Inst 1991 ; 83 : 1013-7.
2. 2. Ashford AR, Donev I, Tiwari RP, Garrett TJ. Reversible ocular toxicity related to tamoxifen therapy. Cancer 1988 ; 61 : 33-5.
3. 3. Bajetta E, Zilembo N, Barni S, Noberasco C, Martinetti A, Ferrari L, et al. A multicentre, randomized, pharmacokinetic, endocrine and clinical study to evaluate formestane in breast cancer patients at first relapse: endocrine and clinical results. The Italian Trials in Medical Oncology (ITMO) group. Ann Oncol 1997 ; 8 : 649-54.
4. 4. Bajetta E, Zilembo N, Noberasco C, Martinetti A, Mariani L, Ferrari L, et al. The minimal effective exemestane dose for endocrine activity in advanced breast cancer. Eur J Cancer 1997 ; 33 : 587-91.
5. 5. Bates T, Riley DL, Houghton J, Fallowfield L, Baum M. Breast cancer in elderly women : a Cancer Research Campaign trial comparing treatment with tamoxifen and optimal surgery with tamoxifen alone. The Elderly Breast Cancer Working Party. Br J Surg 1991 ; 78 : 591-4.
6. 6. Bergh J, Bonneterre J, Illiger HJ, Murray R, Nortier J, Paridaens R, et al. Vorozole (Rivizor) versus arninoglutethimide (AG) in the treatment of postmenopausal breast cancer relapsing after tamoxifen (Meeting abstract). Proc Annu Meet Am Soc Clin Oncol 1997 ; 16 : A543.
7. 7. Berliere M, Charles A, Galant C, Donnez J. Uterine side effects of tamoxifen : a need for systematic pretreatment screening. Obstet Gynecol 1998 ; 91 : 40-4.
8. 8. Bernoux A, de Cremoux P, Laine-Bidron C, Martin EC, Asselain B, Magdelenat H. Estrogen receptor negative and progesterone receptor positive primary breast cancer: pathological characteristics and clinical outcome. Institut Curie Breast Cancer Study Group. Breast Cancer Res Treat 1998 ; 49 : 219-25.
9. 9. Bernstein L, Deapen D, Cerhan JR, Schwartz SM, Liff J, McGann-Maloney E, et al. Tamoxifen therapy for breast cancer and endometrial cancer risk. J Natl Cancer Inst 1999 ; 91 : 1654-62.
10. 10. Bertelli G, Venturini M, Del Mastro L, Garrone O, Cosso M, Gustavino C, et al. Tamoxifen and the endometrium : findings of pelvic ultrasound examination and endometrial biopsy in asymptomatic breast cancer patients. Breast Cancer Res Treat 1998 ; 47 : 41-6.
11. 11. Bezwoda WR, Gudgeon A, Falkson G, Jordaan JP, Goedhals L. Fadrozole venus megestrol acetate : a double-blind randomised trial in advanced breast cancer. Oncology 1998 ; 55 : 416-20.
12. 12. Bezwoda WR, Mansoor N, Dansey R. Correlation of breast tumour aromatase activity and response to aromatase inhibition with aminoglutethimide. Oncology 1987 ; 44 : 345-9.
13. 13. Boccardo F, Rubagotti A, Amoroso D, Sismondi P, Genta F, Nenci I, et al. Chemotherapy versus tamoxifen versus chemotherapy plus tamoxifen in node-positive, oestrogen-receptor positive breast cancer patients. An update at 7 years of the 1st Grocta (Breast Cancer Adjuvant Chemo-Hormone Therapy Cooperative Group) trial. Eur J Cancer 1992 ; 28 : 673-80.
14. 14. Boccardo F, Rubagotti A, Perrotta A, Amoroso D, Balestrero M, De Matteis A, et al. Ovarian ablation versus goserelin with or without tamoxifen in pre-perimenopausal patients with advanced breast cancer : results of a multicentric Italian study. Ann Oncol 1994 ; 5 : 337-42.
15. 15. Bonneterre J. Hormonothérapie des cancers du sein : les produits. In: Brémond A, Rouëssé J, Kerbrat P, Fumoleau P, editors. Cancer du sein : 20 ans de progrès. Meudon : Publications Médicales Internationales, 1994 : 485-92.
16. 16. Bonneterre J, Coppens H, Mauriac L, Metz M, Rouesse J, Armand JP, et al. Aminoglutethimide in advanced breast cancer : clinical results of a French multicenter randomized trial comparing 500 mg and 1 g/day. Eur J Cancer Clin Oncol 1985 ; 21 : 1153-8.
17. 17. Buzdar AU, Jonat W, Howell A, Jones SE, Blomqvist CP, Vogel CL, et al. Anastrozole versus megestrol acetate in the treatment of postmenopausal women with advanced breast carcinoma : results of a survival update based on a combined analysis of data from two mature phase III trials. Arimidex Study Group [published erratum appears in Cancer 1999 15 ; 85 : 1010]. Cancer 1998 ; 83 : 1142-52.
18. 18. Byrne MJ, Gebski V, Forbes J, Tattersall MH, Simes RJ, Coates AS, et al. Medroxyprogesterone acetate addition or substitution for tamoxifen in advanced tamoxifen-resistant breast cancer: a phase III randomized trial. Australian-New Zealand Breast Cancer Trials Group. J Clin Oncol 1997 ; 15: 3141-8.
19. 19. Cameron DA, Anderson EDC, Levack P, Hawkins RA, Anderson TJ, Leonard, et al. Primary systemic therapy for operable breast cancer - 10-year survival data after chemotherapy and hormone therapy. Br J Cancer 1997 ; 76 : 1099-105.
20. 20. Castiglione Gertsch M, Johnsen C, Goldhirsch A, Gelber RD, Rudenstam CM, Collins J, et al. The International (Ludwig) Breast Cancer Study Group Trials I-IV : 15 years follow-up. Ann Oncol 1994 ; 5 : 717-24.
21. 21. Cecchini S, Ciatto S, Bonardi R, Mazzota A, Pacini P, Muraca MG, et al. Risk of endometrial cancer in breast cancer patients under long-term adjuvant treatment with tamoxifen. Tumori 1998 ; 84 : 21-3.
22. 22. Cohen I, Perel E, Tepper R, Flex D, Figer A, Shapira J, et al. Dose-dependent effect of tamoxifen therapy on endometrial pathologies in postmenopausal breast cancer patients. Breast Cancer Res Treat 1999 ; 53 : 255-62.
23. 23. Cohen I, Rosen DJ, Altaras M, Beyth Y, Shapira J, Yigael D. Tamoxifen treatment in premenopausal breast cancer patients may be associated with ovarian overstimulation, cystic formations and fibroid overgrowth. Br J Cancer 1994 ; 69 : 620-1.
24. 24. Colletta AA, Benson JR, Baum M. Alternative mechanisms of action of anti-oestrogens. Breast Cancer Res Treat 1994 ; 31 : 5-9.
25. 25. Costantino JP, Kuller LH, Ives DG, Fisher B, Dignam J. Coronary heart disease mortality and adjuvant tamoxifen therapy. J Natl Cancer Inst 1997 ; 89 : 776-82.
26. 26. Preliminary results from the cancer research campaign trial evaluating tamoxifen duration in women aged fifty years or older with breast cancer. Current Trials working Party of the Cancer Research Campaign Breast Cancer Trials Group [published erratum appears in J Natl Cancer Inst 1997 16 ; 89 : 590]. J Natl Cancer Inst 1996 ; 88 : 1834-9.
27. 27. Cuenca RE, Giachino J, Arredondo MA, Hempling R, Edge SB. Endometrial carcinoma associated with breast carcinoma : low incidence with tamoxifen use. Cancer 1996 ; 77 : 2058-63.
28. 28. Curtis RE, Boice JD, Shriner DA, Hankey BF, Fraumeni JF. Second cancers after adjuvant tamoxifen therapy for breast cancer. J Natl Cancer Inst 1996 ; 88 : 832-4.
29. 29. Cutuli B, Petit JC, Fricker JP, Schumacher C, Velten M, Abecassis J. Accidents thromboemboliques chez les patientes ménopausées sous traitement adjuvant par ramoxifène. Fréquence, facteurs de risque et possibilités de prévention. Bull Cancer 1995 ; 82 : 51-6.
30. 30. Dalberg K, Johansson H, Johansson U, Rutqvist LE. A randomized trial of long term adjuvant tamoxifen plus postoperative radiation therapy versus radiation therapy alone for patients with early stage breast carcinoma treated with breast-conserving surgery. Stockholm Breast Cancer Study Group. Cancer 1998 ; 82 : 2204-11.
31. 31. Damewood MD, Schlaff WD, Hesla JS, Rock JA. Interval bone mineral density with long-term gonadotropin-releasing hormone agonist suppression. Fertil Steril 1989 ; 52 : 596-9.
32. 32. Davidson N, O'Neill A, Vukov A, Osborne CK, Martino S, White D, et al. Effect of chemohormonal therapy in premenopausal, node (+), receptor (+) breast cancer : an Eastern Cooperative Oncology Group III Intergroup trial (E5188, INT-0101). Proc Annu Meet Am Soc Clin Oncol 1999 ; 18 : A249.
33. 33. Delozier T, Spielmann M, Mace-Lesech J, Janvier M, Luboinski M, Asselain B, et al. Short-term versus lifelong adjuvant tamoxifen in early breast cancer (EBC) : a randomized trial (TAM-01) (Meeting abstract). Proc Annu Meet Am Soc Clin Oncol 1997 ; 16 : A451.
34. 34. Delozier T, Switsers O, Genot JY, Ollivier JM, Hery M, Namer M, et al. Tamoxifène adjuvant retardé dans le cancer du sein curable. Résultats d'un essai coopératif randomisé. Bull Cancer 1997 ; 84 : 25-30.
35. 35. Dixon JM, Love CD, Renshaw L, Bellamy C, Cameron DA, Miller WR, et al. Lessons from the use of aromatase inhibitors in the neoadjuvant setting. Endocr Relat Cancer 1999 ; 6 : 227-30.
36. 36. Dombernowsky P, Smith I, Falkson G, Leonard R, Panasci L, Bellmunt J, et al. Letrozole, a new oral aromatase inhibitor for advanced breast cancer : double-blind randomized trial showing a dose effect and improved efficacy and tolerability compared with megestrol acetate. J Clin Oncol 1998 ; 16 : 453-61.
37. 37. Systemic treatment of early breast cancer by hormonal, cytotoxic, or immune therapy. 133 randomised trials involving 31,000 recurrences and 24,000 deaths among 75,000 women. Early Breast Cancer Trialists' Collaborative Group. Lancet 1992 ; 339 : 1-15.
38. 38. Systemic treatment of early breast cancer by hormonal, cytotoxic, or immune therapy. 133 randomised trials involving 31,000 recurrences and 24,000 deaths among 75,000 women. Early Breast Cancer Trialists' Collaborative Group. Lancet 1992 ; 339 : 71-85.
39. 39. Ovarian ablation in early breast cancer : overview of the randomised trials. Early Breast Cancer Trialists' Collaborative Group. Lancet 1996 ; 348 : 1189-96.
40. 40. Polychemotherapy for early breast cancer : an overview of the randomised trials. Early Breast Cancer Trialists' Collaborative Group. Lancet 1998 ; 352 : 930-42.
41. 41. Tamoxifen for early breast cancer : an overview of the randomised trials. Early Breast Cancer Trialists' Collaborative Group. Lancet 1998 ; 351 : 1451-67.
42. 42. Ejlertsen B, Dombernowsky P, Mouridsen HT, Kamby K, Kjaer M, Rose C. Comparable effect of ovarian ablation (OA) and CMF chemotherapy in premenopausal hormone receptor positive breast cancer patients (PRP). Proc Annu Meet Am Soc Clin Oncol 1999 ; 18 : A248.
43. 43. Ellis PA, Saccani-Jotti G, Clarke R, Johnston SR, Anderson E, Howell, et al. Induction of apoptosis by tamoxifen and ICI 182780 in primary breast cancer. Int J Cancer 1997 ; 72 : 608-13.
44. c ed. Paris: Frison-Roche, 1990.
45. 45. Etienne MC, Milano G, Frenay M, Renee N, Francois E, Thyss A, et al. Pharmacokinetics and pharmacodynamics of medroxyprogesterone acetate in advanced breast cancer patients [published erratum appears in J Clin Oncol 1992 ; 10 : 1988]. J Clin Oncol 1992 ; 10 : 1176-82.
46. 46. Fervers B, Bonichon F, Demard F, Heron JF, Mathoulin S, Philip T, et al. Méthodologie de développement des standards, options et recommandations diagnostiques et thérapeutiques en cancérologie. Bull Cancer 1995 ; 82 : 761-7.
47. 47. Fisher B, Costantino J, Redmond C, Wickerham DL. Recent information from current NSABP trials of adjuvant therapy for breast cancer. In : Salmon SE, ed. Adjuvant therapy of cancer VII. Lippincott Company, 1993 : 148-61.
48. 48. Fisher B, Costantino JP, Redmond CK, Fisher ER, Wickerham DL, Cronin WM. Endometrial cancer in tamoxifen-treated breast cancer patients : findings from the National Surgical Adjuvant Breast and Bowel Project (NSABP) B-14. J Natl Cancer Inst 1994 ; 86 : 527-37.
49. 49. Fisher B, Dignam J, Bryant J, DeCillis A, Wickerham DL, Wolmark N, et al. Five versus more than five years of tamoxifen therapy for breast cancer patients with negative lymph nodes and estrogen receptor-positive tumors. J Natl Cancer Inst 1996 ; 88 : 1529-42.
50. 50. Fisher B, Dignam J, Wieand S, Wolmark N, Wickerham DL. Duration of tamoxifen (TAM) therapy for primary breast cancer: 5 versus 10 years (NSABP B-14). Proc Annu Meet Am Soc Clin Oncol 1996 ; 15 : 118A.
51. 51. Fisher B, Dignam J, Wolmark N, DeCillis A, Emir B, Wickerham DL, et al. Tamoxifen and chemotherapy for lymph node-negative, estrogen receptor-positive breast cancer. J Natl Cancer Inst 1997 ; 89 : 1673-82.
52. 52. Fisher B, Redmond C, Legault Poisson S, Dimitrov NV, Brown AM, Wickerham DL, et al. Postoperative chemotherapy and tamoxifen compared with tamoxifen alone in the treatment of positive-node breast cancer patients aged 50 years and older with tumors responsive to tamoxifen : results from the National Surgical Adjuvant Breast and Bowel Project B-16. J Clin Oncol 1990 ; 8 : 1005-18.
53. 53. Fisher B, Redmond CK, Wolmark N. Long term results from NSABP trials of adjuvant therapy for breast cancer. In : Salmon SE, ed. Adjuvant therapy of cancer V. Philadelphia : W.B. Saunders Company, 1987 : 283-93.
54. 54. Focan C, Beauduin M, Salamon E, De Wasch G, Driesschaert P, Lobelle JP, et al. Influence of age, node involvement and CMF chemotherapy on the outcome of early breast cancer treated with hight dose medroxyprogesterone acetate (HD-MPA) as adjuvant hormonotherapy : 5 years results of a randomized trial. In : Salmon SE, ed. Adjuvant therapy of cancer VI. Philadelphia : WB Saunders Company, 1990 : 319-29.
55. 55. Fornander T, Hellstrom AC, Moberger B. Descriptive clinicopathologic study of 17 patients with endometrial cancer during or after adjuvant tamoxifen in early breast cancer. J Natl Cancer Inst 1993 ; 85 : 1850-5.
56. 56. Gazet JC, Markopoulos C, Ford HT, Coombes RC, Bland JM, Dixon RC. Prospective randomised trial of tamoxifen versus surgery in elderly patients with breast cancer. Lancet 1988 ; 1 : 679-81.
57. 57. Gelber RD, Cole BF, Goldhirsch A, Rose C, Fisher B, Osborne CK, et al. Adjuvant chemotherapy plus tamoxifen compared with tamoxifen alone for postmenopausal breast cancer : meta-analysis of quality-adjusted survival. Lancet 1996 ; 347 : 1066-71.
58. 58. Gelber RD, Goldhirsch A. A new endpoint for the assessment of adjuvant therapy in postmenopausal women with operable breast cancer. J Clin Oncol 1986 ; 4 : 1772-9.
59. 59. Gershanovich M, Chaudri HA, Campos D, Lurie H, Bonaventura A, Jeffrey, et al. Letrozole, a new oral aromatase inhibitor : randomised trial comparing 2,5 mg daily, 0,5 mg daily and aminoglutethimide in postmenopausal women with advanced breast cancer. Letrozole International Trial Group (AR/BC3). Ann Oncol 1998 ; 9 : 639-45.
60. 60. Gershanovich M, Garin A, Baltina D, Kurvet A, Kangas L, Ellmen J. A phase III comparison of two toremifene doses to tamoxifen in postmenopausal women with advanced breast cancer. Eastern European Study Group. Breast Cancer Res Treat 1997 ; 45 : 251-62.
61. 61. Gershanovich M, Hayes DF, Ellmen J, Vuorinen J. High-dose toremifene versus tamoxifen in postmenopausal advanced breast cancer. Oncology 1997 ; 11 (5 suppl. 4) : 29-36.
62. 62. Goldhirsch A, Gelber RD. Adjuvant chemo-endocrine therapy or endocrine therapy alone for postmenopausal patients : Ludwig Studies III and IV. Recent Results Cancer Res 1989 ; 115 : 153-62.
63. 63. Goldhirsch A, Gelber RD, Castiglione M, Price KN, Rudenstam CM, Lindtner J, et al. Present and future projects of the International Breast Cancer Study Group. Cancer 1994 ; 74 (suppl. 3) : 1139-49.
64. 64. Gorin MB, Day R, Costantino JP, Fisher B, Redmond CK, Wickerham L, et al. Long-term tamoxifen citrate use and potential ocular toxicity. Am J Ophthalmol 1998 ; 125 : 493-501.
65. 65. GOSS P, Wine E, Tannock I, Schwartz IH, Kremer AB for the North, American VSG. Vorozole versus Megace in postmenopausal patients with metastatic breast carcinoma who had relapsed following tamoxifen. Proc Annu Meet Am Soc Clin Oncol 1997 ; 16 : A542.
66. 66. Gudmundsson JA, Ljunghall S, Bergquist C, Wide L, Nillius SJ. Increased bone turnover during gonadotropin-releasing hormone superagonist-induced ovulation inhibition. J Clin Endocrinol Metab 1987 ; 65 : 159-63.
67. 67. Harmsen HJ, Porsius AJ. Endocrine therapy of breast cancer. Eur J Cancer Clin Oncol 1988 ; 24 : 1099-116.
68. 68. Holli K. Evolving role of toremifene in the adjuvant setting. Oncology 1997 ; 11 (5 suppl. 4) : 48-51.
69. 69. Holli K. Adjuvant trials of toremifene versus tamoxifen : the European experience. Oncology 1998 ; 12 (3 suppl. 5) : 23-7.
70. 70. Howell A, DeFriend DJ, Robertson JF, Blamey RW, Anderson L, Anderson E, et al. Pharmacokinetics, pharmacological and anti-tumour effects of the specific anti-oestrogen ICI 182780 in women with advanced breast cancer. Br J Cancer 1996 ; 74 : 300-8.
71. 71. Hupperets P, Wils J, Volovics L, Schouten L, Fickers M, Bron H, et al. Adjuvant chemo-hormonal therapy with cyclophosphamide, doxorubicin and 5-fluorouracil (CAF) with or without medroxyprogesterone acetate for node-positive cancer patients. Update at 7-year follow-up. Ann Oncol 1995 ; 6 : 90-1.
72. 72. Hupperets PS, Wils J, Volovics L, Schouten L, Fickers M, Bron H, et al. Adjuvant chemohormonal therapy with cyclophosphamide, doxorubicin and 5-fluorouracil (CAF) with or without medroxyprogesterone acetate for node-positive breast cancer patients. Ann Oncol 1993 ; 4 : 295-301.
73. 73. Effectiveness of adjuvant chemotherapy in combination with tamoxifen for node-positive postmenopausal breast cancer patients. International Breast Cancer Study Group. J Clin Oncol 1997 ; 15 : 1385-94.
74. 74. Ingle JN, Johnson PA, Suman VJ, Gerstner JB, Mailliard JA, Camoriano, et al. A randomized phase II trial of two dosage levels of letrozole as third-line hormonal therapy for women with metastatic breast carcinoma. Cancer 1997 ; 80 : 218-24.
75. 75. Jakesz R, Hausmaninger H, Samonigg H, Kubista E, Depisch D, Fridik M. Comparison of adjuvant therapy with tamoxifen and goserelin versus CMF in premenopausal stage I and II hormone-responsive breast cancer patients : four-year results of Austrian Breast Cancer Study Group (ABCSG) trial 5. Proc Annu Meet Am Soc Clin Oncol 1999 ; 18 : A250.
76. 76. Jonat W, Santen RJ. Aromatase inhibition : present and future. The Partenon Publishing Group, 1991.
77. 77. Jones AL, Powles TJ, Law M, Tidy A, Easton D, Coombes RC, et al. Adjuvant aminoglutethimide for postmenopausal patients with primary breast cancer : analysis at 8 years. J Clin Oncol 1992 ; 10 : 1547-52.
78. 78. Jordan VC. Molecular mechanisms of antiestrogen action in breast cancer. Breast Cancer Res Treat 1994 ; 31 : 41-52.
79. 79. Kaiser-Kupfer MI, Lippman ME. Tamoxifen retinopathy. Cancer Treat Ref 1978 ; 62 : 315-20.
80. 80. Katase K, Sugiyama Y, Hasumi K, Yoshimoto M, Kasumi F. The incidence of subsequent endometrial carcinoma with tamoxifen use in patients with primary breast carcinoma. Cancer 1998 ; 82 : 1698-703.
81. 81. Katzenellenbogen BS, Miller MA, Mullick A, Sheen YY. Antiestrogen action in breast cancer cells : modulation of proliferation and protein synthesis, and interaction with estrogen receptors and additional antiestrogen binding sites. Breast Cancer Res Treat 1985 ; 5 : 231-43.
82. 82. Katzenellenbogen BS, Montano MM, Ekena K, Herman ME, McInerney EM. Antiestrogens : mechanisms of action and resistance in breast cancer. William E. McGuire Memorial Lecture. Breast Cancer Res Treat 1997 ; 44 : 23-38.
83. 83. Kaufmann M, Jonat W, Abel U, Hilfrich J, Caffier H, Kreienberg R, et al. Adjuvant randomized trials of doxorubicin/cyclophosphamide versus doxorubicin/cyclophosphamide/tamoxifen and CMF chemotherapy versus tamoxifen in women with node-positive breast cancer. J Clin Oncol 1993 ; 11 : 454-60.
84. 84. Kenny FS, Robertson JFR, Ellis IO, Elston CW, Blamey RW. Long-term follow-up of elderly patients randomized to primary tamoxifen or wedge mastectomy as initial therapy for operable breast cancer. Breast 1998 ; 7 : 335-9.
85. 85. Kleeberg UR, Dowsett M, Carrion RP, Dodwell DJ, Vorobiof DA, Aparicio, et al. A randomised comparison of oestrogen suppression with anastrozole and formestane in postmenopausal patients with advanced breast cancer. Oncology 1997 ; 54 (suppl. 2) : 19-22.
86. 86. Le Bouedec G, de Latour M, Feillel V, Dauplat J. Métrorragies et tamoxifène : à propos de 22 patientes traitées pour cancer du sein. J Gynecol Obstet Biol Reprod 1990 ; 19 ; 889-94.
87. 87. Le Bouedec G, Pingeon JM, Fondrinier E, Kauffmann P, Dauplat J. Surveillance gynécologique des traitements du cancer du sein par le tamoxifène. Rev Fr Gynecol Obstet 1995 ; 90 : 379-82.
88. 88. Le Bouedec G, Ptak Y, Ronayette H, Lemery S, Dauplat J. L'hydromètre postménopausique : influence du tamoxifène. Rev Fr Gynecol Obstet 1994 ; 89 : 597-601.
89. 89. Levenson AS, Jordan VC. Selective oestrogen receptor modulation : molecular pharmacology for the millennium. Eur J Cancer 1999 ; 35 : 1628-39.
90. 90. Levine MN, Gent M, Hirsh J, Arnold A, Goodyear MD, Hryniuk W, et al. The thrombogenic effect of anticancer drug therapy in women with stage II breast cancer. N Engl J Med 1988 ; 318 : 404-7.
91. 91. Love CD, Muir BB, Scrimgeour JB, Leonard RC, Dillon P, Dixon JM. Investigation of endometrial abnormalities in asymptomatic women treated with tamoxifen and an evaluation of the role of endometrial screening. J Clin Oncol 1999 ; 17 : 2050-4.
92. 92. Marty M, Gershanovich M, Campos B, Romieu G, Lurie H, Bonaventura T, et al. Letrozole, a new potent, selective aromatase inhibitor (AI) superior to aminoglutethimide (AG) in postmenopausal women with advanced breast cancer (ABC) previously treated with anti-estrogens. Proc Annu Meet Am Soc Clin Oncol 1997 ; 16 : A544.
93. 93. Matta WH, Shaw RW, Hesp R, Katz D. Hypogonadism induced by luteinising hormone releasing hormone agonist analogues : effects on bone density in premenopausal women. Br Med J Clin Res Ed 1987 ; 294: 1523-4.
94. 94. Mauriac L, Asselain B, Blanc-Vincent MP, Cutuli B, Dilhuydy JM, Fourquet A, et al. Fédération nationale des centres de lutte contre le cancer, ed. Cancers du sein non métastatiques. Paris : Arnette Blackwell. 1996 ; 1-348. (Standards, Options et Recommandations, vol. 3).
95. 95. Mauriac L, Durand M, Chauvergne J, Bonichon F, Avril A, Mage P, et al. Adjuvant trial for stage II receptor-positive breast cancer : CMF versus CMF-tamoxifen in a single centre. Breast Cancer Res Treat 1988 ; 11 : 179-86.
96. 96. Mauriac L, Durand M, Floquet A, Tchen N, Bonichon F. First line tamoxifen for invasive hormonal sensitive non metastatic breast carcinomas in young postmenopausal patients. Breast Cancer Res Treat 1999 ; 57 : 435.
97. 97. Meier CR, Jick H. Tamoxifen and risk of idiopathic venous thromboembolism. Br J Clin Pharmacol 1998 ; 45 : 608-12.
98. 98. Mignotte H, Lasset C, Bonadona V, Lesur A, Luporsi E, Rodier JF, et al. Iatrogenic risks of endometrial carcinoma after treatment for breast cancer in a large French case-control study. Federation nationale des centres de lutte contre le cancer (FNCLCC). Int J Cancer 1998 ; 76 : 325-30.
99. 99. Mignotte H, Rodier JF, Lesur A, Hoffstetter S, Cutuli B, D'Anjou J, et al. Endometrial carcinoma associated with adjuvant tamoxifen therapy for breast cancer : a French multi-centre analysis of 89 cases. Breast 1995 ; 4 : 200-2.
100. 100.Mouridsen HT, Rose C, Overgaard M, Dombernowsky P, Panduro J, Thorpe S, et al. Adjuvant treatment of postmenopausal patients with high risk primary breast cancer : results from the Danish adjuvant trials DBCG 77 C and DBCG 82 C. Acta Oncol 1988 ; 27 : 699-705.
101. 101. Nawaz Z, Stancel CM, Hyder SM. The pure antiestrogen ICI 182,780 inhibits progestin-induced transcription. Cancer Res 1999 ; 59 : 372-6.
102. 102. Nayfield SG, Gorin MB. Tamoxifen-associated eye disease : a review. J Clin Oncol 1996 ; 14 : 1018-26.
103. 103. Neven P, Vergote I. Controversies regarding tamoxifen and uterine carcinoma. Curr Opin Obstet Gynecol 1998 ; 10 : 9-14.
104. 104. Neven P, Vernaeve H. Guidelines for monitoring patients taking tamoxifen treatment. Drug Saf 2000 ; 22 : 1-11.
105. 105. Nomura Y, Tashiro H, Hisamatsu K, Shinozuka K. A randomized trial of adjuvant endocrine therapy, chemotherapy, and chemoendocrine therapy for operable breast cancer stratified by estrogen receptors. Cancer 1988 ; 61 : 2168-75.
106. 106. Pannuti F, Martoni A, Piana E, Guaraldi M. Progestins in breast cancer. Hormonotherapy: results and perspectives. Adv Clin Oncol 1988 ; 3 : 207-22.
107. 107. Pavlidis NA, Petris C, Briassoulis E, Klouvas G, Psilas C, Rempapis J, et al. Clear evidence that long-term, low-dose tamoxifen treatment can induce ocular toxicity. A prospective study of 63 patients. Cancer 1992 ; 69: 2961-4.
108. 108. Powles T, Eeles R, Ashley S, Easton D, Chang J, Dowsett M, et al. Interim analysis of the incidence of breast cancer in the Royal Marsden Hospital tamoxifen randomised chemoprevention trial. Lancet 1998 ; 352: 98-101.
109. 109. Powles TJ, Bourne T, Athanasiou S, Chang J, Grubock K, Ashley S, et al. The effects of norethisterone on endometrial abnormalities identified by transvaginal ultrasound screening of healthy post-menopausal women on tamoxifen or placebo. Br J Cancer 1998 ; 78 : 272-5.
110. 110. Powles TJ, Jones AL, Ashley SE, O'Brien ME, Tidy VA, Treleavan J, et al. The Royal Marsden Hospital pilot tamoxifen chemoprevention trial. Breast Cancer Res Treat 1994 ; 31 : 73-82.
111. 111. Pritchard KI, Paterson AH, Paul NA, Zee B, Fine S, Pater J. Increased thromboembolic complications with concurrent tamoxifen and chemotherapy in a randomized trial of adjuvant therapy for women with breast cancer. National Cancer Institute of Canada Clinical Trials Group Breast Cancer Site Group. J Clin Oncol 1996 ; 14 : 2731-7.
112. 112. Pritchard KI, Paterson AHG, Fine S, Paul NA, Zee B, Shepherd LE, et al. Randomized trial of cyclophosphamide, methotrexate, and fluorouracil chemotherapy added to tamoxifen as adjuvant therapy in postmenopausal women with node-positive estrogen and/or progesterone receptor-positive breast cancer : a report of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 1997 ; 15 : 2302-11.
113. 113. Pugesgaard T, Von Eyben FE. Bilateral optic neuritis evolved during tamoxifen treatment. Cancer 1986 ; 58 : 383-6.
114. 114. Pyrhonen S, Valavaara R, Modig H, Pawlicki M, Pienkowski T, Gundersen, et al. Comparison of toremifene and tamoxifen in post-menopausal patients with advanced breast cancer : a randomized double-blind, the 'nordic' phase III study. Br J Cancer 1997 ; 76 : 270-7.
115. 115. Ragaz J, Coldman A. Survival impact of adjuvant tamoxifen on competing causes of mortality in breast cancer survivors, with analysis of mortality from contralateral breast cancer, cardiovascular events, endometrial cancer, and thromboembolic episodes. J Clin Oncol 1998 ; 16 : 2018-24.
116. 116. Ragaz J, Jackson SM, Wilson KS, Plenderleith IH, Knowling M, Basco V. Randomized study of locoregional radiotherapy (XRT) and ovarian ablation (OOPH) in premenopausal patients with breast cancer treated with adjuvant chemotherapy (CT). Proc Annu Meet Am Soc Clin Oncol 1988 ; 7 : A45.
117. 117. Resch A, Biber E, Seifert M, Resch H. Evidence that tamoxifen preserves bone density in late postmenopausal women with breast cancer. Acta Oncol 1998 ; 37 : 661-4.
118. 118. Ribeiro G, Swindell R. The Christie hospital adjuvant tamoxifen trial-status at 10 years. Br J Cancer 1988 ; 57 : 601-3.
119. 119. Riis BJ, Christiansen C, Johansen JS, Jacobson J. Is it possible to prevent bone loss in young women treated with luteinizing hormone-releasing hormone agonists ? J Clin Endocrinol Metab 1990 ; 70 : 920-4.
120. 120. Rivkin S, Green S, Metch B, Cruz A, Tesh D, Glick J, et al. Adjuvant combination chemotherapy (CMFVP) versus oophorectomy followed by CMFVP (OCMFVP) for premenopausal women with ER+ operable breast cancer with positive (+) axillary lymph nodes : an intergroup study. Proc Annu Meet Am Soc Clin Oncol 1991 ; 10 : A64.
121. 121. Rivkin SF, Green S, Metch B, Cruz AB, Abeloff MD, Jewell WR, et al. Adjuvant CMFVP versus tamoxifen versus concurrent CMFVP and tamoxifen for postmenopausal, node-positive, and estrogen receptor-positive breast cancer patients : a Southwest Oncology Group study. J Clin Oncol 1994 ; 12 : 2078-85.
122. 122. Rivkin SE, Green S, O'Sullivan J, Cruz AB, Abeloff MD, Jewell WR, et al. Adjuvant CMFVP versus adjuvant CMFVP plus ovariectomy for premenopausal, node-positive, and estrogen receptor-positive breast cancer patients : a Southwest Oncology Group study. J Clin Oncol 1996 ; 14 : 46-51.
123. 123. Robertson JF, Ellis IO, Elston CW, Blamey RW. Mastectomy or tamoxifen as initial therapy for operable breast cancer in elderly patients : 5-year follow-up. Eur J Cancer 1992 ; 28A : 908-10.
124. 124. Rochefort H. Antihormones stéroïdes et cancers du sein. In : Bellon, ed. Cancer du sein : 20 ans de progrès. I. Biologie du cancer du sein : progrès récents. Meudon : Publications Médicales Internationales, 1994 : 171-5.
125. 125. Roché H, Mihura J, de Lafontan B, Reme-Saumon M, Martel P, Dubois JB, et al. Castration and tamoxifen versus chemotherapy (FAC) for premenopausal, node and receptors positive breast cancer patients : a randomized trial with a 7 years median follow up. Proc Annu Meet Am Soc Clin Oncol 1996 ; 15 : A134.
126. 126. Russell CA, Green SJ, O'Sullivan J, Hynes HE, Budd GT, Congdon JE, et al. Megestrol acetate and aminoglutethimide/hydrocortisone in sequence or in combination as second-line endocrine therapy of estrogen recepror-positive metastatic breast cancer : a southwest oncology group phase III trial. J Clin Oncol 1997 ; 15 : 2494-501.
127. 127. Rutqvist LE. Zoladex® and tamoxifen as adjuvant therapy in premenopausal breast cancer : a randomised trial by the Cancer Research Campain (CRC) Breast Cancer Trial Group, the Stockholm Breast Cancer Study Group, the South-East Sweden Breast Cancer Group & the Gruppo Interdisciplinare Valutazione Interventi in Oncologica (GIVIO). Proc Annu Meet Am Soc Clin Oncol 1999 ; 18 : A251.
128. 128. Rutqvist LE, Cedermark B, Fornander T, Glas U, Johansson H, Nordenskjold B, et al. The relationship between hormone receptor content and the effect of adjuvant tamoxifen in operable breast cancer. J Clin Oncol 1989 ; 7 : 1474-84.
129. 129. Rutqvist LE, Johansson H, Signomklao T, Johansson U, Fornander T, Wilking N. Adjuvant tamoxifen therapy for early stage breast cancer and second primary malignancies. Stockholm Breast Cancer Study Group. J Natl Cancer Inst 1995 ; 87 : 645-51.
130. 130. Saphner T, Tormey DC, Gray R. Venous and arterial thrombosis in patients who received adjuvant therapy for breast cancer. J Clin Oncol 1991 ; 9 : 286-94.
131. 131. Randomized trial of two versus five years of adjuvant tamoxifen for postmenopausal early stage breast cancer. Swedish Breast Cancer Cooperative Group. J Natl Cancer Inst 1996 ; 88 : 1543-9.
132. 132. Scharla SH, Minne HW, Waibel Treber S, Schaible A, Lempert UG, Wuster C, et al. Bone mass reduction after estrogen deprivation by long-acting gonadotropin-releasing hormone agonists and its relation to pretreatment serum concentrations of 1,25-dihydroxyvitamin D3. J Clin Endocrinol Metab 1990 ; 70 : 1055-61.
133. 133. Adjuvant ovarian ablation versus CMF chemotherapy in premenopausal women with pathological stage II breast carcinoma : the Scottish trial. Scottish Cancer Trials Breast Group and ICRF Breast Unit, Guy's Hospital, London. Lancet 1993 ; 341 : 1293-8.
134. 134. Shushan A, Peretz T, Uziely B, Lewin A, Mor-Yosef S. Ovarian cysts in premenopatisal and postmenopausal tamoxifen-treated women with breast cancer. Am J Obstet Gynecol 1996 ; 174 (1 Pt 1) : 141-4.
135. 135. Stewart HJ. The Scottish trial of adjuvant tamoxifen in node-negative breast cancer. Scottish Cancer Trials Breast Group. Monogr Natl Cancer Inst 1992 ; 11 : 117-20.
136. 136. Stewart HJ, Forrest AP, Everington D, McDonald CC, Dewar JA, Hawkins RA, et al. Randomised comparison of 5 years of adjuvant tamoxifen with continuous therapy for operable breast cancer. The Scottish Cancer Trials Breast Group. Br J Cancer 1996 ; 74 : 297-9.
137. 137. Tang R, Shields J, Schiffman J, Li H, Locher D, Hampton J, et al. Retinal changes associated with tamoxifen treatment for breast cancer. Eye 1997 ; 11 : 295-7.
138. 138. Taylor CW, Green S, Dalton WS, Martino S, Rector D, Ingle JN, et al. Multicenter randomized clinical trial of goserelin versus surgical ovariectomy in premenopausal patients with receptor-positive metastatic breast cancer : an intergroup study. J Clin Oncol 1998 ; 16 : 994-9.
139. 139. Thurlimann B, Castiglione M, Hsu-Schmitz SF, Cavalli F, Bonnefoi H, Fey MF, et al. Formestane versus megestrol acetate in postmenopausal breast cancer patients after failure of tamoxifen : a phase III prospective randomised cross over trial of second-line hormonal treatment (SAKK 20/90). Swiss Group for Clinical Cancer Research (SAKK). Eur J Cancer 1997 ; 33 : 1017-24.
140. 140. Tormey DC, Gray R, Falkson HC. Postchemotherapy adjuvant tamoxifen therapy beyond five years in patients with lymph node-positive breast cancer. Eastern Cooperative Oncology Group. J Natl Cancer Inst 1996 ; 88 : 1828-33.
141. 141. Tormey DC, Gray R, Gilchrist K, Grage T, Carbone PP, Woher J. et al. Adjuvant chemohormonal therapy with cyclophosphamide, methotrexate, 5-fluorouracil, and prednisone (CMFP) or CMFP plus tamoxifen compared with CMF for premenopausal breast cancer patients. An Eastern Cooperative Oncology Group trial. Cancer 1990 ; 65 : 200-6.
142. 142. Tummon IS, Ali A, Pepping ME, Radwanska E, Binor Z, Dmowski WP. Bone mineral density in women with endometriosis before and during ovarian suppression with gonadotropin-releasing hormone agonists or danazol. Fertil Steril 1988 ; 49 : 792-6.
143. 143. van Leeuwen FE, Benraadt J, Coebergh JW, Kiemeney LA, Gimbrere CH, Otter R, et al. Risk of endometrial cancer after tamoxifen treatment of breast cancer. Lancet 1994 ; 343 : 448-52.
144. 144. Vrbanec D, Reiner Z, Belev B, Plestina S. Changes in serum lipid and lipoprotein levels in postmenopausal patients with node-positive breast cancer treated with tamoxifen. Tumori 1998 ; 84 : 687-90.
145. 145. Waibel Treber S, Minne HW, Scharla SH, Bremen T, Ziegler R, Leyendecker G. Reversible bone loss in women treated with GnRH-agonists for endometriosis and uterine leiomyoma. Hum Reprod 1989 ; 4 : 384-8.
146. 146. Willsher PC, Robertson JF, Chan SY, Jackson L, Blamey RW. Locally advanced breast cancer: early results of a randomised trial of multimodal therapy versus initial hormone therapy. Eur J Cancer 1997 ; 33 : 45-9.
147. 147. Wils JA, Bliss JM, Marty M, Coombes G, Fontaine C, Morvan F, et al. Epirubicin plus tamoxifen versus tamoxifen alone in node-positive post-menopausal patients with breast cancer : a randomized trial of the International Collaborative Cancer Group. J Clin Oncol 1999 ; 17 : 1988-98.